Sana Biotechnology director receives 8,680 shares

The director's award consisted of fully vested restricted stock units; the reported post-transaction direct common-stock position was 5,863,480 shares.

Rhea-AI Filing Summary

Sana Biotechnology, Inc. director Hans Edgar Bishop acquired 8,680 shares of common stock on October 5, 2026. The award consisted of fully vested restricted stock units. His reported direct common-stock holdings following the transaction were 5,863,480 shares.

Insider Trade Summary

Grant/Award: 8,680 shares

Grant/Award 1 txn

Insider Bishop Hans Edgar

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	8,680	$0.00	$0.00

Holdings After Transaction: Common Stock — 5,863,480 shares (Direct)

Footnotes (1)

1. F1. Consists of fully vested restricted stock units.

Key Figures

Shares acquired: 8,680 shares Direct common-stock holdings after transaction: 5,863,480 shares

2 metrics

Shares acquired 8,680 shares Award on October 5, 2026

Direct common-stock holdings after transaction 5,863,480 shares Reported following the October 5, 2026 award

Key Terms

restricted stock units, fully vested

2 terms

restricted stock units financial

"Consists of fully vested restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

fully vested financial

"Consists of fully vested restricted stock units."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did SANA director Hans Edgar Bishop receive?

Hans Edgar Bishop acquired 8,680 shares of Sana Biotechnology common stock on October 5, 2026. The award consisted of fully vested restricted stock units.

How many Sana Biotechnology shares did Hans Edgar Bishop hold after the award?

His reported direct common-stock holdings following the transaction were 5,863,480 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/06/2026 - 04:42 PM Accepted by SEC EDGAR 10/06/2026 - 04:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bishop Hans Edgar

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 350

(Street)

SEATTLE WASHINGTON 98102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/05/2026		A		8,680(1)	A	$0.00	5,863,480	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of fully vested restricted stock units.

Remarks:

	/s/ Aaron M. Grossman, Attorney-in-Fact for Hans Edgar Bishop	10/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)